Bevacizumab and Trastuzumab With Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer

Exclusion Criteria

• •Previous chemotherapy treatment.
• •Previous treatment with HER2 or VEGF inhibitors.
• •Pulmonary disease not controlled.
• •Hypertension not controlled (systolic \> 150 mmHg and/or diastolic \> 100 mmHg) or significant cardiovascular disease (CVA/cerebral hemorrhage (6 months before inclusion), myocardial infarction (6 months before inclusion), unstable angina, congestive cardiac disease ≥ NYHA 2, or serious cardiac arrhythmia requiring medication.
• •Antecedents of coagulopathy or clinically significant thrombosis.
• •Major surgery, open biopsy or significant trauma 28 days before the inclusion in the study or planned major surgery during the study.
• •Peripheral Neuropathy \> CTC 2 at inclusion.
• •Altered renal function a. Creatinine \> 2.0 mg/dL or 177 mmol/L. b.Proteinuria \> 2+ with reactive stick(dipstick). If screening proteinuria 2+, collection of 24h urine must show a value of proteins of 1 g/24h.
• •Daily chronic treatment with corticosteroids
• •Daily chronic treatment with aspirin (\> 325 mg/day) o clopidogrel (\> 75 mg/day)
• •Antecedents or heritage evidence of bleeder diathesis or coagulopathy with risk of hemorrhage.
• •Antecedents of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months previous to the inclusion.
• •Active infection to be treated with iv antibiotics
• •Serious injury not curing, peptic ulcer or bone fracture.
• •Pregnant or active sexual patient not using contraceptive methods. or lactating woman
• •Current or recent treatment with another IMP or participation in another clinical trial (30 days before inclusion)
• •Another primary tumor (including primary brain tumors)within 5 years to the study inclusion, apart from in situ cervix carcinoma, skin squamous carcinoma, both if they are appropriately treated, or skin basal cell cancer if controlled.